William R. Rohn joined our board of directors as the chairman in connection with Pfenex’s initial public offering in July 2014. Most recently, Mr. Rohn served as Chief Operating Officer of Biogen Idec, the successor company to IDEC Pharmaceuticals, a biotechnology company, from 2003 until 2005. Mr. Rohn also held various management positions with IDEC Pharmaceuticals, a biotechnology company, including: President and Chief Operating Officer from 1998 to 2003, Senior Vice President, Commercial Operations from 1996 to 1998 and Senior Vice President, Commercial and Corporate Development from 1993 to 1996. He also held various management positions with Adria Laboratories, a pharmaceutical company acquired by Pfizer Inc., including: Senior Vice President of Commercial Operations from 1991 to 1993 and Vice President of Business Development and Licensing from 1985 to 1990. Mr. Rohn currently serves on the board of directors of Hansen Medical, Inc., a medical device company. Mr. Rohn previously served on the boards of Intellikine, Inc., a pharmaceutical company acquired by Takeda America Holdings, Inc., Cerus Corporation, a biomedical products company, Elan Corporation, plc, a pharmaceutical company acquired by Perrigo Company plc, Metabasis Therapeutics, Inc., a biopharmaceutical company that merged with Ligand Pharmaceuticals Inc., and Pharmacyclics Inc., a pharmaceutical company. Mr. Rohn holds a Bachelor’s degree in Marketing from Michigan State University and has completed graduate-level coursework in Business Administration at Indiana State University.
Dr. Campbell joined our board of directors in September 2014. He has over 25 years of experience in pharmaceutical and biotechnology sales, marketing, product development and general management in both the U.S. and in international markets. Currently he serves as Chairman of the Board of Aptitude Medical Systems, an early stage company creating high performance aptamers for research, diagnostic and therapeutic use. He is also a Lecturer in the Technology Management Program of the College of Engineering at the University of California at Santa Barbara. From 2004 to 2008, Dr. Campbell was President and CEO of Naryx Pharma, a venture-backed specialty pharmaceutical company developing novel, topically delivered treatments for chronic sinusitis and other conditions treatable by intranasal drug delivery. Prior to joining Naryx Pharma, Dr. Campbell was at Amgen from 1989 to 2002, where his most recent position was Vice President and General Manager, U.S. Oncology Business Unit. In this position, he led an integrated team responsible for the marketing, sales and medical development of products generating over $1 billion of annual sales including Neupogen and Neulasta. His professional experience also includes sales, marketing and managerial responsibilities with Ciba-Geigy Corporation from 1984 to 1989. He earned a Bachelor of Arts in Zoology at the University of North Carolina at Chapel Hill, and a Ph.D. in Microbiology and Immunology at the Bowman Gray School of Medicine of Wake Forest University.
Bert Liang is a serial entrepreneur, scientist and clinician. He is a founding CEO of Pfenex Inc., a biosimilar development company, and led the company’s successful IPO (NYSE MKT: PFNX) and secondary financings. As CEO, he was selected as inaugural Chair, BioDefense Advisory Committee for BIO (Biotechnology Industry Organization), where he leads and advocates for policies in the Biodefense Industry, and inaugural Chair, the Biosimilars Council, a division of GPhA (Generic Pharmaceuticals Association), the leading voice for the Biosimilars Industry. He was previously founder, Chairman and CEO of Tracon Pharma (NASDAQ: TCON); founder and Chairman, Coronado Biosciences (NASDAQ: CNDO); Site Head Biogen, in charge of Pre-clinical and Clinical Development and Vice President, New Ventures (partnered with MPM Capital). Previously at IDEC, he was Vice President and Head, Hematology and Oncology. Dr. Liang joined IDEC from Amgen, where he led the development to approval of various cytokines including NeulastaÒ. Dr. Liang has held academic positions at the NCI, University of Colorado and University of Vermont, where he headed Human Medical Genetics. Dr. Liang is an alumnus of the Feinberg School of Medicine at Northwestern University, the Institute of Materials Research and Innovation, University of Bolton, the University of London, Regis University, the MIT Sloan School of Management, and trained in internal medicine at Brown University, Neurology and Oncology at the University of Michigan, with post-doctoral studies in molecular biology and genetics at the NCHGR and NCI at NIH. He has authored over 75 peer-reviewed publications, chapters and books, and edited a number of volumes in the fields of Neurology and Oncology, such as Hematology-Oncology Clinics of North America, Neuro-oncology, published by Harcourt (now Elsevier) and is the author of two management books, including Pragmatic MBA for the Scientific and Technical Executive, and Managing and Leading for Science Professionals (What I wished I’d known when moving up the Management Ladder) both published by Elsevier (Academic Press).
Phillip M. Schneider joined our board in connection with Pfenex’s initial public offering in July 2014. Most recently, Mr. Schneider held various positions with IDEC Pharmaceuticals Corporation, a biopharmaceutical company, from 1987 to 2003, including: Senior Vice President and Chief Financial Officer from 1997 to 2003; and Director of Finance and Administration from 1992 to 1997. Prior to that, Mr. Schneider held various management positions at Syntex Pharmaceuticals Corporation, a pharmaceutical company, from 1985 to 1987 and KPMG LLP, an audit and tax advisory firm, from 1982 to 1984, where he attained his CPA license. He currently serves as a member of the board of directors of Arena Pharmaceuticals Corporation, a pharmaceutical company, which he joined in 2008, and Auspex Pharmaceuticals, a pharmaceutical company, which he joined in 2014. He previously served as a member of the board of directors of Gen-Probe, Inc., a biotechnology company, from 2002 to 2012. Mr. Schneider holds a B.S. in Biochemistry from the University of California, Davis and an M.B.A. from the University of Southern California.
John Taylor joined our board of directors in April 2015. He is a Principal at Greenleaf Health LLC., and has over 24 years of experience working on Food and Drug related issues at the at the U.S. Food and Drug Administration (FDA) and in private industry. He is a member of Greenleaf’s Compliance & Regulatory Affairs group. Prior to joining Greenleaf in 2014, he served in three positions at FDA: Counselor to the Commissioner; Acting Deputy Principal Commissioner; and Acting Deputy Commissioner for Global Regulatory Operations and Policy.
John began his career at FDA as an attorney within FDA’s Office of the Chief Counsel in 1991. In 1997, John was promoted to Senior Advisor for Regulatory Operations and Policy within FDA’s Office of the Commissioner; he was later named Director of the Center for Drug Evaluation and Research’s Office of Compliance. In 2000, John became the Director of the Office of Enforcement in FDA’s Office of Regulatory Affairs (ORA). Two years later, John was promoted to Associate Commissioner for Regulatory Affairs. In that role he was responsible for managing ORA.
In 2005, John left FDA and spent four years working in the private sector, first as Divisional Vice President for Federal Government Affairs at Abbott, then, in 2007, as Executive Vice President for Health at the Biotechnology Industry Organization. He also served on the Board of Directors for the Food and Drug Law Institute from 2007 to 2009. In 2009, John returned to FDA.
John received a Bachelor of Arts in History from Pennsylvania State University and a Juris Doctorate degree from the College of William and Mary.
Dennis Fenton joined the board of directors in September 2015, deepening the manufacturing and product development expertise of our company. Dr. Fenton, an industry pioneer, has over three decades of experience in the biotechnology industry.
Dr. Fenton retired after a lengthy and distinguished career with Amgen, where he held a variety of notable roles, including Executive Vice President, Operations. Prior to Amgen, he was a senior researcher with Pfizer. Dr. Fenton most recently served on the board of directors of Hospira, Dendreon Corporation, Genzyme and Amira Pharmaceuticals.
He is an alumnus of Rutgers University, where he graduated with a Ph.D. in microbiology. Dr. Fenton currently serves as a member of the board of directors for Portola Pharmaceuticals, XenoPort, Nora Therapeutics, and Kythera Biopharmaceuticals.